[1] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018; 36: 1953−2041. doi: 10.1097/HJH.0000000000001940 [2] Benetos A, Petrovic M, Strandberg T. Hypertension management in older and frail older patients. Circ Res 2019; 124: 1045−1060. doi: 10.1161/CIRCRESAHA.118.313236 [3] Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557−1562. doi: 10.1001/jama.1996.03530440037034 [4] [5] Seifarth C, Trenkel S, Schobel H, et al. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol 2002; 57: 457−465. doi: 10.1046/j.1365-2265.2002.01613.x [6] Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet 2014; 383: 1899−1911. doi: 10.1016/S0140-6736(14)60685-1 [7] Harbaoui B, Courand PY, Defforges A, et al. Cumulative effects of several target organ damages in risk assessment in hypertension. Am J Hypertens 2016; 29: 234−244. doi: 10.1093/ajh/hpv098 [8] Rossignol P, Hosseini K, Tropeano AI, et al. Target organ damage assessment in French hypertensive patients without established cardiovascular or renal disease: results of the PREVENT-A study. J Hypertens 2013; 31: 177−185. doi: 10.1097/HJH.0b013e32835a34bb [9] Courand PY, Harbaoui B, Bècle C, et al. Plasma NT-proBNP mirrors the deleterious cardiovascular and renal continuum in hypertension. Eur J Prev Cardiol 2017; 24: 452−459. doi: 10.1177/2047487316683070 [10] Chen H, Lowe AA, Bai Y, et al. Evaluation of a portable recording device (ApneaLink) for case selection of obstructive sleep apnea. Sleep Breath 2009; 13: 213−219. doi: 10.1007/s11325-008-0232-4 [11] Courand PY, Grandjean A, Charles P, et al. R Wave in aVL Lead is a Robust Index of Left Ventricular Hypertrophy: A Cardiac MRI Study. Am J Hypertens 2015; 28: 1038−1048. doi: 10.1093/ajh/hpu268 [12] Reference Values for Arterial Stiffness’ Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J 2010; 31: 2338−2350. doi: 10.1093/eurheartj/ehq165 [13] Berge C, Courand PY, Harbaoui B, et al. Decreased plasma prorenin levels in primary aldosteronism: potential diagnostic implications. J Hypertens 2015; 33: 118−125. doi: 10.1097/HJH.0000000000000367 [14] Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1526−1540. doi: 10.1210/jc.2008-0125 [15]

Courand PY, Dinic M, Lorthioir A, et al. Resistant hypertension and atherosclerotic renal artery stenosis: effects of angioplasty on ambulatory blood pressure. a retrospective uncontrolled single-center study. Hypertension 2019; 74: 1516−1523.

[16] [17] Laurent S, Boutouyrie P. Arterial stiffness and hypertension in the elderly. Front Cardiovasc Med 2020; 7: 544302. doi: 10.3389/fcvm.2020.544302 [18] Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55: 1318−1327. doi: 10.1016/j.jacc.2009.10.061 [19] Gosse P, Jan E, Coulon P, et al. ECG detection of left ventricular hypertrophy: the simpler, the better? J Hypertens 2012; 30: 990−996. doi: 10.1097/HJH.0b013e3283524961 [20] Courand PY, Jenck S, Bricca G, et al. R wave in aVL lead: an outstanding ECG index in hypertension. J Hypertens 2014; 32: 1317−1325. doi: 10.1097/HJH.0000000000000181 [21] Verdecchia P, Angeli F, Cavallini C, et al. The voltage of R wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy. J Hypertens 2009; 27: 1697−1704. doi: 10.1097/HJH.0b013e32832c0031 [22] Jain A, Tandri H, Dalal D, et al. Diagnostic and prognostic utility of electrocardiography for left ventricular hypertrophy defined by magnetic resonance imaging in relationship to ethnicity: The Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J 2010; 159: 652−658. doi: 10.1016/j.ahj.2009.12.035 [23] Courand PY, Gaudebout N, Mouly-Bertin C, et al. Biological, electrical and echocardiographic indices versus cardiac magnetic resonance imaging in diagnosing left ventricular hypertrophy. Hypertens Res 2014; 37: 444−451. doi: 10.1038/hr.2013.147 [24] Aro AL, Chugh SS. Clinical diagnosis of electrical versus anatomic left ventricular hypertrophy: prognostic and therapeutic implications. Circ Arrhythm Electrophysiol 2016; 9: e003629. doi: 10.1161/CIRCEP.115.003629 [25]

Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J 2014; 35: 1245–1254.

[26] Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371: 1921−1926. doi: 10.1016/S0140-6736(08)60834-X [27]

Takeda M, Yamamoto K, Akasaka H, et al. Clinical characteristics and postoperative outcomes of primary aldosteronism in the elderly. J Clin Endocrinol Metab 2018; 103: 3620–3629.

[28] Eschalier R, McMurray JJV, Swedberg K, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 2013; 62: 1585−1593. doi: 10.1016/j.jacc.2013.04.086 [29] ASTRAL Investigators, Wheatley K, Ives N, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009; 361: 1953−1962. doi: 10.1056/NEJMoa0905368 [30]

Cooper CJ, Murphy TP, Cutlip DE, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2017; 370: 13−22.

[31]